2,4-thiazolidinedione has been researched along with Metabolic Syndrome in 14 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 diabetes is a multiorgan disease that results from the combination of insulin resistance and a beta-cell secretory defect." | 2.42 | The need for reappraisal of type 2 diabetes mellitus management. ( Wyne, KL, 2003) |
| "Patients with type 2 diabetes frequently manifest multiple risk factors for cardiovascular morbidity and mortality." | 2.42 | Insulin resistance syndrome. Description, pathogenesis, and management. ( Miller, JL, 2003) |
| "Insulin resistance is associated with VAT products, such as free fatty acids and their metabolites, as well as cytokines, such as tumour necrosis factor alpha (TNF-alpha)." | 2.42 | The relationship of obesity to the metabolic syndrome. ( Lebovitz, HE, 2003) |
| "Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities." | 2.42 | Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. ( Ayyobi, AF; Brunzell, JD, 2003) |
| "For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population." | 2.41 | A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. ( Hoogwerf, BJ; Nambi, V; Sprecher, DL, 2002) |
| "Troglitazone was the first drug which reached the market." | 2.41 | [Thiazolidinediones--a new class of oral antidiabetic drugs]. ( Csermely, P; Jermendy, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (85.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geurin, MD | 1 |
| St Anna, L | 1 |
| Benetti, E | 1 |
| Patel, NS | 1 |
| Collino, M | 1 |
| Zimmet, P | 1 |
| Nambi, V | 1 |
| Hoogwerf, BJ | 1 |
| Sprecher, DL | 1 |
| Wyne, KL | 2 |
| Miller, JL | 1 |
| Gurnell, M | 1 |
| Savage, DB | 1 |
| Chatterjee, VK | 1 |
| O'Rahilly, S | 1 |
| Lebovitz, HE | 1 |
| Ayyobi, AF | 1 |
| Brunzell, JD | 1 |
| Dagogo-Jack, S | 1 |
| Jermendy, G | 1 |
| Csermely, P | 1 |
| Cadoudal, T | 1 |
| Leroyer, S | 1 |
| Reis, AF | 1 |
| Tordjman, J | 1 |
| Durant, S | 1 |
| Fouque, F | 1 |
| Collinet, M | 1 |
| Quette, J | 1 |
| Chauvet, G | 1 |
| Beale, E | 1 |
| Velho, G | 1 |
| Antoine, B | 1 |
| Benelli, C | 1 |
| Forest, C | 1 |
13 reviews available for 2,4-thiazolidinedione and Metabolic Syndrome
| Article | Year |
|---|---|
Thiazolidinedione therapy for managing metabolic syndrome.
Topics: Humans; Hypoglycemic Agents; Ligands; Metabolic Syndrome; Thiazolidinediones; Treatment Outcome | 2010 |
The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.
Topics: Animals; Cardiovascular Diseases; Disease Management; Humans; Ligands; Metabolic Syndrome; PPAR delt | 2011 |
Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Metabolic Syndrome; Thiazoles; Thiazolidinedio | 2002 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertrigly | 2002 |
The need for reappraisal of type 2 diabetes mellitus management.
Topics: Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Metabol | 2003 |
Insulin resistance syndrome. Description, pathogenesis, and management.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Risk Factors; Thiazoles; | 2003 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agent | 2003 |
The relationship of obesity to the metabolic syndrome.
Topics: Adiponectin; Adipose Tissue; Blood Proteins; Body Constitution; Humans; Hypoglycemic Agents; Hypolip | 2003 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2003 |
Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management.
Topics: Blood Circulation; Diabetes Mellitus, Type 2; Environmental Exposure; Female; Genetic Predisposition | 2003 |
Free fatty acids and type 2 diabetes mellitus.
Topics: Adipocytes; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; | 2003 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Piogl | 2001 |
Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome.
Topics: Adipocytes; Adrenal Cortex Hormones; Animals; Esterification; Fatty Acids, Nonesterified; Gene Expre | 2005 |
1 other study available for 2,4-thiazolidinedione and Metabolic Syndrome
| Article | Year |
|---|---|
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Proceedings of a symposium. November 6-8, 2002, New York, New York, USA.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Met | 2003 |